Growth factor receptors and related signalling pathways as targets for novel treatment strategies of hepatocellular cancer.

ABSTRACT: Growth factors and their corresponding receptors are commonly overexpressed and/or dysregulated in many cancers including hepatocellular cancer (HCC). Clinical trials indicate that growth factor receptors and their related signalling pathways play important roles in HCC cancer etiology and progression, thus providing rational targets for innovative cancer therapies. A number of strategies including monoclonal antibodies, tyrosine kinase inhibitors ("small molecule inhibitors") and antisense oligonucleotides have already been evaluated for their potency to inhibit the activity and downstream signalling cascades of these receptors in HCC. First clinical trials have also shown that multi-kinase inhibition is an effective novel treatment strategy in HCC. In this respect sorafenib, an inhibitor

SUBMITTER: Hopfner M 

PROVIDER: S-EPMC2673371 | biostudies-literature | 2008 Jan

REPOSITORIES: biostudies-literature